Rogers Corp (ROG)

68.44
0.93 1.38
NYSE : Technology
Prev Close 67.51
Open 67.65
Day Low/High 66.93 / 68.64
52 Wk Low/High 41.92 / 69.26
Volume 160.39K
Avg Volume 130.70K
Exchange NYSE
Shares Outstanding 18.00M
Market Cap 1.23B
EPS 2.50
P/E Ratio 26.55
Div & Yield N.A. (N.A)

Latest News

Roche Receives FDA Approval For Use Of SurePath Preservative Fluid With Cobas HPV Test For Cervical Cancer Screening

Roche Receives FDA Approval For Use Of SurePath Preservative Fluid With Cobas HPV Test For Cervical Cancer Screening

Roche HPV test is first to be approved for use with the SurePath Preservative Fluid gynecologic cell collection medium commonly used for Pap tests

FDA Approves Genentech's Xolair® (omalizumab) For Allergic Asthma In Children

FDA Approves Genentech's Xolair® (omalizumab) For Allergic Asthma In Children

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Rogers Corporation To Participate In CJS Securities, Inc. Sixteenth Annual

Rogers Corporation To Participate In CJS Securities, Inc. Sixteenth Annual "New Ideas" Summer Conference

Rogers Corporation (NYSE:ROG) will be participating in the Sixteenth Annual CJS Securities "New Ideas" Summer Conference on Tuesday, July 12, 2016 in White Plains, NY.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

FDA Grants Priority Review For Genentech's OCREVUS™ (ocrelizumab) Biologics License Application

FDA Grants Priority Review For Genentech's OCREVUS™ (ocrelizumab) Biologics License Application

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.

Sanofi's Likely Sweetener for Medivation Panned

Sanofi's Likely Sweetener for Medivation Panned

The French drugmaker is reportedly thinking about including a CVR in its $9.3 billion bid for Medivation, but the move is unlikely to be enough to entice the target's shareholders.

Roche Receives FDA Clearance For Its Procalcitonin (PCT) Assay To Help Clinicians Effectively Assess Sepsis Risk And Manage Sepsis Patients

Roche Receives FDA Clearance For Its Procalcitonin (PCT) Assay To Help Clinicians Effectively Assess Sepsis Risk And Manage Sepsis Patients

First IVD company to provide a fully integrated solution for PCT testing with Elecsys BRAHMS PCT

Phase III Study Shows Genentech's Actemra® (tocilizumab) Maintained Steroid-Free Remission In People With Giant Cell Arteritis (GCA)

Phase III Study Shows Genentech's Actemra® (tocilizumab) Maintained Steroid-Free Remission In People With Giant Cell Arteritis (GCA)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III study known as GiACTA, which evaluated Actemra ® (tocilizumab) in people with giant cell...

Genentech's Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Shrank Tumors In People With Previously Untreated Advanced Bladder Cancer

Genentech's Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Shrank Tumors In People With Previously Untreated Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that in a Phase II study, IMvigor 210, TECENTRIQ™ (atezolizumab) shrank tumors (objective response rate, ORR) in 24 percent (n=28)...

FDA Grants First Liquid Biopsy Approval To The Roche Cobas® EGFR Mutation Test V2

FDA Grants First Liquid Biopsy Approval To The Roche Cobas® EGFR Mutation Test V2

Test can be used with either plasma or tumor tissue, as a companion diagnostic for non-small cell lung cancer therapy

Genentech's Gazyva® Showed Superior Progression-Free Survival Compared To Rituxan® In People With Previously Untreated Follicular Lymphoma

Genentech's Gazyva® Showed Superior Progression-Free Survival Compared To Rituxan® In People With Previously Untreated Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the pivotal Phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of...

Insider Trading Alert - DEPO, ARIA And ROG Traded By Insiders

Insider Trading Alert - DEPO, ARIA And ROG Traded By Insiders

Stocks with insider trader activity include DEPO, ARIA and ROG

Roche Announces The First FDA-approved CMV Test For Use In Hematopoietic Stem Cell Transplant Recipients

Roche Announces The First FDA-approved CMV Test For Use In Hematopoietic Stem Cell Transplant Recipients

New test standardizes CMV testing for both solid organ and hematopoietic stem cell transplant recipients

Roxgold Grants Stock Options

Roxgold Grants Stock Options

Phase III Study Of Genentech's Alecensa® (Alectinib) Showed Superior Efficacy Versus Crizotinib In Japanese People With A Specific Type Of Lung Cancer

Phase III Study Of Genentech's Alecensa® (Alectinib) Showed Superior Efficacy Versus Crizotinib In Japanese People With A Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that Alecensa ® (alectinib), an oral anaplastic lymphoma kinase (ALK) inhibitor, reduced the risk of disease worsening or death...

FDA Grants Genentech's Cancer Immunotherapy TECENTRIQ™ (atezolizumab) Accelerated Approval For People With A Specific Type Of Advanced Bladder Cancer

FDA Grants Genentech's Cancer Immunotherapy TECENTRIQ™ (atezolizumab) Accelerated Approval For People With A Specific Type Of Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Rogers Corporation To Participate In The B. Riley & Co.'s 17th Annual Investor Conference

Rogers Corporation To Participate In The B. Riley & Co.'s 17th Annual Investor Conference

Rogers Corporation (NYSE:ROG) will be participating in the Seventeenth Annual B.

Insider Trading Alert - RRD, KLIC And ROG Traded By Insiders

Insider Trading Alert - RRD, KLIC And ROG Traded By Insiders

Stocks with insider trader activity include RRD, KLIC and ROG

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABCD, ABX, AEG, AMBC, AZN, BK, CBG, CBT, CNA, CSTE, DO, EEP, GBX, GRC, HHC, NWFL, OFIX, RJF, ROG, RVSB, SBAC, SCCO, SLM, TOT Downgrades: ATRC, BSFT, CZNC, PCRX, VICR, WTM Initiations: RYAM Read on to get TheStreet Quant Ratings' detailed report:

Strong On High Volume: Rogers (ROG)

Strong On High Volume: Rogers (ROG)

Trade-Ideas LLC identified Rogers (ROG) as a strong on high relative volume candidate

Genentech Highlights Personalized Medicines And Cancer Immunotherapies At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech Highlights Personalized Medicines And Cancer Immunotherapies At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced new results from 19 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual...

Rogers Corporation Reports First Quarter 2016 Results

Rogers Corporation Reports First Quarter 2016 Results

Rogers Corporation (NYSE:ROG) today announced financial results for the 2016 first quarter.

US Insurance Coverage For Harmony Prenatal Test From Roche Expands To 200 Million Covered Lives

US Insurance Coverage For Harmony Prenatal Test From Roche Expands To 200 Million Covered Lives

In-network status for non-invasive prenatal test now includes four largest national private health plans and Medi-Cal

Rogers Corporation Invites You To Join Its 2016 First Quarter Earnings Conference Call

Rogers Corporation Invites You To Join Its 2016 First Quarter Earnings Conference Call

Rogers Corporation (NYSE: ROG) plans to announce results for its 2016 first quarter after the close of trading on Monday, May 2, 2016.